The clinical data from abiraterone acetate and MDV-3100 confirm continued androgen receptor (AR) addiction in a significant proportion of castration-resistant prostate cancers (CRPC). However, patients nearly invariably progress with a rise in prostate-specific antigen, suggesting resumption of ...
HRPCHormone-Refractory Prostate Cancer HRPCHormone-Resistant Prostate Cancer HRPCHigh Risk Pregnancy Center(various locations) HRPCHouse Republican Policy Committee(US House of Representatives) HRPCHudson River Parks Conservancy HRPCHigh-Resolution Performance Counter(timer) ...
The two randomized trials that supported the approval of docetaxel (Taxotere) for hormone-resistant prostate cancer (HRPC) treated a heterogeneous group of patients, approximately 30% of whom had symptomatic bone pain. Because of known toxicities, chemotherapy had traditionally been admin...
No systemic therapy has led to prolongation of life in patients with hormone resistant prostate cancer though secondary hormone treatment and chemotherapy have resulted in an about 30% response rate. The main goal of treatment is palliation and improvement of quality of life, the former aim ...
Analysis of survival characteristics and prognostic factors in 148 patients with hormone-resistant (stage D3) prostate cancer North American Conference on Cancer in Hispanics (1991), p. A33 Google Scholar 7. Allain YM, Carteaux A, Chautard D, Daver A, Geslin J, Malkani K, Pulci S Relevance...
If your PSA levels go up, it’s a sign that the cancer has started growing again. If this happens, your cancer is considered castrate-resistant, and hormone deprivation therapy is no longer an effective treatment. You’ll also get other blood tests to see if the cancer is affecting other...
“We started noticing that the castration resistant prostate cancer models in the lab seemed to express genes that are typically associated with the spread of cancer,” Reiter said. “We began to ask what cell signaling pathways might be responsible. We looked at the androgen receptor and were ...
来源期刊 Cancer Treatment & Research 1996 研究点推荐 hormone-resistant prostate cancer hormone-refractory disease 0关于我们 百度学术集成海量学术资源,融合人工智能、深度学习、大数据分析等技术,为科研工作者提供全面快捷的学术服务。在这里我们保持学习的态度,不忘初心,砥砺前行。了解更多>> 友情链接 联系我们 ...
November 23rd 2024 PSMA-Targeted Radiation Drug for Prostate Cancer Subset Meets Study Goal Ryan Scott Patients with PSMA-positive metastatic castration-resistant prostate cancer showed benefits after receiving PSMA-targeted treatment. About Advertise / Support Contact CancerNetwork.com TargetedOnc.com OncL...
No systemic therapy has led to prolongation of life in patients with hormone resistant prostate cancer though secondary hormone treatment and chemotherapy have resulted in an about 30% response rate. The main goal of treatment is palliation and improvement of quality of life, the former aim obtain...